The SU2C-Dutch Cancer Society Tumor Organoids Dream Team developed a groundbreaking technology that allows tumor samples isolated from patients to be maintained and grown in the laboratory setting. These growing tumors, which are called “tumor organoids,” provide an unprecedented opportunity to combine DNA sequence analyses with functional studies of tumors from individual patients. Most importantly, these tumor organoids will allow studies of sensitivity and resistance to a large number of anticancer drugs in the lab.